Raphael J. Landovitz, MD, MSc
Raphael Landovitz, MD, MSc, is Associate Professor of Medicine at the UCLA Center for Clinical AIDS Research & Education. He is also the new Center Co-Director of CHIPTS. He has led combination prevention intervention studies and projects using Post-exposure (PEP) and Pre-exposure (PrEP) strategies for MSM, as well as being part of leadership groups of the DAIDS-funded AIDS Clinical Trials Group (ACTG), HIV Prevention Trials Network (HPTN) and the former Adolescent Trials Network (ATN). He is chair of the ACTG Antiretroviral Strategies Scientific Committee, the principal investigator of two multisite PrEP demonstration project in Los Angeles County, and leads the NIH/DAIDS-funded Phase 2 and Phase 3 registrational clinical trials evaluating long-acting injectable Cabotegravir for PrEP. His research agenda focuses on the optimization of the use of antiretroviral medications for both HIV treatment and HIV prevention.